#1 Clinical Trials Search in Europe

Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein, Recombinant

Recent clinical trials are investigating the use of INBRX-101, a novel drug containing Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein (Recombinant), for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. These studies aim to evaluate the safety, efficacy, and long-term effects of INBRX-101 compared to existing treatments. The trials focus on adults with AATD emphysema and explore various aspects of the drug’s performance, including its pharmacokinetics, pharmacodynamics, and potential benefits for patients with this rare genetic condition.

Table of Contents

What is INBRX-101?

INBRX-101 is a new medication being developed to treat a condition called Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. It’s a type of drug known as a recombinant protein, which means it’s made in a laboratory to mimic a natural protein in the body[1]. The full name of the active substance in INBRX-101 is quite long: Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein, Recombinant. This complicated name tells us that the drug is designed to replace a specific protein that people with AATD are missing.

What is AATD Emphysema?

AATD Emphysema is a genetic condition that affects the lungs. People with this condition don’t have enough of a protein called Alpha-1 Antitrypsin (AAT). This protein helps protect the lungs from damage. Without enough AAT, the lungs can become damaged over time, leading to a type of emphysema (a lung disease that makes it hard to breathe)[1][2].

How INBRX-101 Works

INBRX-101 is designed to work by replacing the missing AAT protein in people with AATD. It’s given as an infusion, which means it’s delivered directly into the bloodstream through a vein. The drug is meant to increase the levels of functional AAT (fAAT) in the blood, which can help protect the lungs from further damage[1].

Clinical Trials of INBRX-101

INBRX-101 is currently being studied in clinical trials to test how well it works and how safe it is. There are two main studies happening:

  1. A Phase 2 study comparing INBRX-101 to the current standard treatment (plasma-derived A1PI therapy). This study aims to see how INBRX-101 affects AAT levels in the blood, how the body processes the drug, and how safe it is[1].

  2. A long-term, open-label study to evaluate the safety and effectiveness of INBRX-101 over an extended period. This study will look at how the drug affects lung density (a measure of lung health) and continue to monitor its safety[2].

Potential Benefits of INBRX-101

If successful, INBRX-101 could offer several benefits for people with AATD Emphysema:

  • Increased levels of functional AAT in the blood, potentially slowing down lung damage
  • Possibly fewer infusions needed compared to current treatments (every 3 weeks instead of weekly)
  • Potential improvements in lung density, which could mean better lung function

However, it’s important to remember that these potential benefits are still being studied and haven’t been proven yet[1][2].

Who is Eligible for INBRX-101 Treatment?

Currently, INBRX-101 is only available through clinical trials. The main criteria for participating in these trials include:

  • Being 18-80 years old
  • Having a diagnosis of AATD
  • Having evidence of emphysema due to AATD
  • Having certain levels of lung function (measured by a test called FEV1)
  • Being a non-smoker

There are also several conditions that might prevent someone from participating in the trials, such as certain allergies, other medical conditions, or recent use of other treatments[1][2].

Safety Considerations

As with any new medication, safety is a top priority in the INBRX-101 trials. The researchers are carefully monitoring for any side effects or adverse reactions. Some specific safety considerations include:

  • Potential allergic reactions to the drug
  • The body’s immune response to the drug (called immunogenicity)
  • Any effects on heart function
  • Interactions with other medical conditions or treatments

It’s important to note that all medications can have side effects, and the full safety profile of INBRX-101 is still being determined through these clinical trials[1][2].

Future Outlook

INBRX-101 represents a potentially exciting development in the treatment of AATD Emphysema. If the clinical trials show positive results, it could offer a new option for people living with this condition. However, it’s important to remember that drug development is a long process, and it may be some time before INBRX-101 becomes widely available, if approved.

For now, people with AATD Emphysema should continue to follow their current treatment plans and discuss any questions or concerns with their healthcare providers. They may also want to stay informed about the progress of INBRX-101 and other potential new treatments[1][2].

Aspect Details
Drug Name INBRX-101 (Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein, Recombinant)
Condition Studied Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Trial Phases Phase 2
Main Objectives Evaluate pharmacodynamics, safety, tolerability, and long-term effects
Key Endpoints Changes in functional AAT levels, lung density, adverse events, pharmacokinetics
Dosing Up to 120 mg/kg every 3 weeks
Study Duration Up to 36 months
Participant Age Range 18-80 years

FAQ

  • What is INBRX-101 and how does it work? INBRX-101 is a recombinant protein drug that contains Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein. It is designed to replace the missing or deficient alpha-1 antitrypsin protein in patients with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. By doing so, it aims to protect the lungs from damage caused by excessive enzyme activity.
  • Who is eligible to participate in these clinical trials? The trials are generally open to adults aged 18-80 years with a diagnosis of Alpha-1 Antitrypsin Deficiency (AATD) and evidence of emphysema secondary to AATD. Participants must have specific lung function measurements and be non-smokers. However, there are several exclusion criteria, such as recent use of certain therapies or presence of specific medical conditions.
  • How is INBRX-101 administered in these trials? INBRX-101 is administered as a solution for infusion. In the long-term safety study, participants receive INBRX-101 every 3 weeks (Q3W) at a dose of 120 mg/kg. The exact administration details may vary between different trials.
  • What are the main objectives of these clinical trials? The main objectives of these trials include evaluating the pharmacodynamic effects of INBRX-101 on serum functional AAT levels, assessing its safety and tolerability, studying its pharmacokinetics, and investigating its long-term effects. Some trials also aim to compare INBRX-101 to existing plasma-derived Alpha-1-Proteinase Inhibitor therapies.
  • How long do these clinical trials last? The duration of the trials varies. One study involves a treatment period of up to 32 weeks, while the long-term safety study can last up to 36 months. The exact duration may depend on the specific trial design and objectives.

Ongoing Clinical Trials on Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein, Recombinant

  • Study on Long-Term Safety of INBRX-101 for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

    Not recruiting

    2 1 1
    Investigated drugs:
    Denmark Ireland Poland Spain Sweden

  • Study Comparing INBRX-101 and Human Alpha1-Proteinase Inhibitor for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Ireland Poland Spain Sweden

Glossary

  • Alpha-1 Antitrypsin Deficiency (AATD): A genetic disorder that results in low levels of a protein called alpha-1 antitrypsin in the blood. This can lead to lung and liver disease.
  • Emphysema: A lung condition that causes shortness of breath due to damage to the air sacs in the lungs.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Functional AAT (fAAT): The active form of alpha-1 antitrypsin that can perform its protective function in the body.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Anti-drug antibodies (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which may affect the drug's efficacy or safety.
  • Quantitative CT: A type of computed tomography scan that provides numerical measurements of lung density, used to assess the progression of emphysema.
  • Cor pulmonale: Enlargement of the right side of the heart due to increased pressure in the lungs, often caused by lung diseases like emphysema.
  • COPD exacerbation: A sudden worsening of chronic obstructive pulmonary disease (COPD) symptoms, which can include increased breathlessness, coughing, and mucus production.

References

  1. http://clinicaltrials.eu/trial/study-comparing-inbrx-101-and-human-alpha1-proteinase-inhibitor-for-adults-with-alpha-1-antitrypsin-deficiency-emphysema/
  2. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-inbrx-101-for-adults-with-alpha-1-antitrypsin-deficiency-emphysema/